Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions
The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.
G-CON Manufacturing and Pall Corporation are collaborating to bring turnkey continuous bioprocess or viral vector production facility solutions to the industry. G-CON PODs will be customized with advanced Pall Biotech bioprocess equipment, including automation and utility supplies; these will be predesigned into the G-CON cleanroom units for scalable deployment.
“Together, Pall’s cutting-edge technology and G-CON’s flexible cleanroom platform take the concept of modularity one step further, delivering a complete, reproducible, scalable facility solution that is easy to place or relocate, as well as clean, sanitize and even repurpose,” said Mario Philips, Vice President & General Manager at Pall Biotech. “This strategic collaboration is particularly important to Pall, as we continuously improve bioprocesses for the industry by offering innovative solutions like G-CON PODs customized with Pall technologies. This solution addresses customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing.”
PODs from G-CON are mobile, and include integrated process piping and heating and air conditioning (HVAC) systems. Deploying the customized PODs is simple by design, allowing a customer to focus on the target molecule, while relying on the G-CON and Pall teams to optimize the facility design and process. Once designed, the PODs ease verification, qualification and validation challenges by providing comprehensive site acceptance testing and even IQ/OQ support. The PODs’ flexibility allows them to support multiple products, and they can be easily repurposed. In addition, the cost of 'building' a facility is drastically reduced, as is build time, which increases the return on investment.
“G-CON’s prefabricated cleanroom units feature a complete, yet compressed footprint for Pall’s continuous bioprocessing and viral vector production designs. The implementation of the Pall processes into our POD infrastructure creates an ideal turnkey solution for our customers. These solutions will be readily deployable and scalable, as they reduce the typical design, verification and qualification efforts by standardizing processes and cleanroom environments,” said Maik Jornitz, President and CEO of G-CON Manufacturing. “We are looking forward to combining our PODs with Pall’s process knowledge and designs to serve our joint customer base. The industry requires optimized, fast, scalable solutions, and these requirements will be met through this collaboration.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.